EUCTR2004-003870-27-DK进行中（未招募）1 期
A prospective, collaborative, international, multicentre, randomised, parallel-group, single and outcome blinded, controlled, factorial trial to investigate the safety and efficacy of treatment with transdermal glyceryl trinitrate, a nitric oxide donor, and of continuing or stopping temporarily pre-stroke antihypertensive therapy, in patients with acute stroke
niversity of Nottingham, Research Innovation Services0 个研究点目标入组 5,000 人开始时间: 2011年2月15日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 5,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •a) Adult (age > 18 years).b) Clinical stroke syndrome with limb weakness lasting at least 1 hour (i.e. not likely to be atransient ischaemic attack).c) Residual limb weakness at the time of enrolment (SSS Arm <6 and/or Leg <6, appendix C).d) Onset < 48 hours. If the time of onset is unknown, apply the time when the patient was lastknown to be well. [This timeframe covers the period of maximum uncertainty over alteringblood pressure and should permit the vast majority of otherwise eligible patients to berecruited]e) Conscious (Glasgow Coma Scale > 8).f) Systolic blood pressure in range 140 mmHg to 220 mmHg inclusive on the basis of at leastone of the three baseline pre-randomisation measures.g) Independent prior to stroke (pre-morbid modified Rankin Scale < 2).h) Meaningful consent, or assent from a relative or carer if the patient is unable to givemeaningful consent (e.g. in cases of dysphasia, confusion, or reduced conscious level).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •a) Definite need for nitrate therapy: e.g. concurrent myocardial infarction, unstable angina, leftventricular failure. Patients admitted on nitrates for the management of stable angina maystop these for the 7 day trial treatment period. b) Contraindication to nitrate therapy: e.g. hypersensitivity to nitrates, dehydration,hypovolaemia, hypertrophic obstructive cardiomyopathy, aortic stenosis, cardiactamponade, constrictive pericarditis, mitral stenosis, marked anaemia, closed-angleglaucoma, sildenafil (Viagra) or related drug, within 24 hours.c) Definite need for pre-stroke antihypertensive, anti-anginal or anti-heart failure medication:e.g. concurrent angina, heart failure.d) Definite need for new antihypertensive, anti-anginal or anti-heart failure medication duringacute stroke: e.g. concurrent angina, heart failure, hypertensive encephalopathy, aorticdissection.e) Patients expected, on the basis of existing investigations, to require surgical intervention(e.g. clot evacuation, carotid endarterectomy) during the treatment or follow-up period.) Known intracerebral pathology other than stroke, e.g. subarachnoid haemorrhage, braintumour, cerebral abscess.g) Other serious condition which is likely to prevent outcome assessment at 90 days, e.g.advanced cancer.h) Previous enrolment in ENOS.i) Current involvement in another trial of an experimental drug. [Patients may be randomisedinto observational studies or non-drug trials.]j) Not available for follow-up, e.g. no fixed address, overseas visitor.k) Females of childbearing potential where pregnancy cannot be excluded by a negativepregnancy test, pregnancy, or breastfeeding.l) Need for new antihypertensive therapy to lower systolic blood pressure to achieve theenrolment range of 140-220mmHgm) New (not prescribed pre-stroke) antihypertensive medication commenced after stroke onset
研究者
相似试验
已完成
不适用
Efficacy of nitric oxide in strokeAcute strokeCirculatory SystemStroke, not specified as haemorrhage or infarctionISRCTN99414122niversity of Nottingham (UK)3,500
进行中（未招募）
1 期
The Efficacy of Nitric Oxide in Stroke (ENOS) TrialStrokeEUCTR2004-003870-27-GRniversity of Nottingham, ResearchHead of research grants and contractsInnovation Services4,011
进行中（未招募）
1 期
A prospective, international, multi-centre, open-label, phase II study investigating the utility of [68Ga]Ga-PentixaFor PET imaging in response assessment (evaluation of the tumour response to the applied therapy) of primary (primary tumour in brain) and isolated secondary (secondary tumour in brain after relapse of a primary tumour not located in the brain) CNS lymphoma patientsCentral nervous system (CNS) lymphomaMedDRA version: 21.1Level: PTClassification code 10028997Term: Neoplasm malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-001711-85-NLPentixaPharm GmbH50
撤回
2 期
A prospective, international, multi-centre, open-label,single-arm phase II study investigating the predictive value of [68Ga]Ga-PentixaFor PET imaging in primary and isolated secondary CNS lymphoma patientsCentral Nervous system lymphomaBrain lymphoma10025322Brain tumorNL-OMON51764PentixaPharm GmbH6
进行中（未招募）
1 期
A prospective, international, multi-centre, open-label, phase II study investigating the utility of [68Ga]Ga-PentixaFor PET imaging in response assessment (evaluation of the tumour response to the applied therapy) of primary (primary tumour in brain) and isolated secondary (secondary tumour in brain after relapse of a primary tumour not located in the brain) CNS lymphoma patientsCentral nervous system (CNS) lymphomaMedDRA version: 21.1Level: PTClassification code 10028997Term: Neoplasm malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-001711-85-DKPentixaPharm GmbH50